Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy. The purpose of this study is to evaluate the safety and efficacy of neoadjuvant of tislelizumab combined with platinum doublet for resectable locally-advanced head and neck squamous-cell carcinoma .
Head and Neck Squamous Cell Carcinomas|Resectable Head and Neck Squamous-cell Carcinoma
DRUG: Tislelizumab|DRUG: Nab-paclitaxel|DRUG: Carboplatin
Pathological Complete Response (PCR), From neoadjuvant therapy to surgical resection, up to 6 weeks
Major Pathological Response (MPR), In the pathological examination of resected specimens, the proportion of residual tumor cells was less than 10%., From neoadjuvant therapy to surgical resection, up to 6 weeks|3-year Disease-free survival (DFS) rate, Time from randomization to disease recurrence or death of any cause, 3-years after surgery|3-year overall survival（OS）rate, The proportion of all study cases in which no death from any cause occurred within 3 years after surgery, 3-years after surgery
For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy. The purpose of this study is to evaluate the safety and efficacy of neoadjuvant of tislelizumab combined with platinum doublet for resectable locally-advanced head and neck squamous-cell carcinoma .